These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20494220)

  • 1. Potential mechanisms for HPV vaccine-induced long-term protection.
    Stanley M
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S2-7. PubMed ID: 20494220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
    Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
    Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic human papillomavirus vaccines: past, present and future.
    Anderson LA
    Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the power of prevention: human papillomavirus vaccines.
    Mayeaux EJ
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for the prevention of human papillomavirus infections.
    Speck LM; Tyring SK
    Skin Therapy Lett; 2006; 11(6):1-3. PubMed ID: 16912836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.
    Palmer KE; Jenson AB; Kouokam JC; Lasnik AB; Ghim SJ
    Exp Mol Pathol; 2009 Jun; 86(3):224-33. PubMed ID: 19454268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global stability of equilibria in a two-sex HPV vaccination model.
    Elbasha EH
    Bull Math Biol; 2008 Apr; 70(3):894-909. PubMed ID: 17999117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.